Orexo Provides Information About its New Proprietary Drug Delivery Platform – AmorphOXTM
Orexo AB (publ.),(STO:ORX) (OTCQX:ORXOY) today provides information about its new proprietary drug delivery platform, amorphOXTM, a novel and inventive powder-based technology with significant potential. Several new patent applications directed to amorphOXTM have now been filed, which should serve to protect the technology until 2042.
The amorphOXTM powder technology is made up of particles which are built using a unique combination of a drug, carrier materials and, optionally, other ingredients. The particles are presented as an amorphous composite of the various ingredients providing for excellent chemical and physical stability, commonly a significant problem with amorphous drug compositions.
Significantly, the amorphOXTM platform has been shown to work for a broad scope of different active ingredients enabling drug development in many different fields. Drug products using amorphOXTM display nearly instant dissolution even in very limited amounts of liquids, making it an ideal choice for the development of drugs targeting administration sites such as the nasal and sublingual cavities. Rapid dissolution of drug products provides for important opportunities when, for example, developing drugs requiring a rapid onset of action.
The amorphOXTM platform has been validated in various in vivo studies, including human clinical trials, demonstrating rapid and extensive absorption of various drugs. The platform is well-tolerated and shows a low degree of inter-patient variability. Orexo’s first product based on the amorphOXTM platform, OX124 – an overdose rescue medication – has been shown to provide superior pharmacokinetic properties compared to the market leading liquid-based nasal spray product. The commercial supply chain established for OX124 will help shorten timelines and reduce risk of future products based on nasal delivery.
Development of products based on the amorphOX™ platform will be conducted by Orexo or in partnership with other pharmaceutical companies.
Robert Rönn, SVP and Head of R&D of Orexo AB, said: “Over the last few years, Orexo has taken important steps to continue its pioneering work developing scalable technologies that are helping to create highly differentiated drug products for the treatment of significant unmet medical needs. The development of a proprietary drug delivery platform based on an amorphous drug composition, showing remarkable chemical and physical stability, is a significant invention from the scientists at Orexo and an opportunity for us to continue to develop improved drugs.”
People In This Post
Companies In This Post
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more